Nov
11
2021
On demand

Advancing engineered cell and gene therapy with precision gene editing

With the technological advances over the last decade, we are starting to see the start of a new era in cell and gene therapies. We are now seeing the emergence of clinical therapies that are tackling cancers and diseases with astounding results. This has really initiated the motivation in the field to see what other life changing treatments that can be created and whether this can be done safely.

A strong motivator in the cell and gene therapy space is to have treatments that can eradicate all current (and future) cancers. The approach to this has been predominantly focused on utilising our own immune system to be able to recognise and eliminate the cancerous cells. These immune-oncology therapies have been focused on haematological/liquid cancers, with astounding success, but given that this makes up a small subset of disorders there is a strong motivation to design therapies against more complex solid tumours. Solid tumours, however, offer extra complexities due to the tumour microenvironment and requires more complex strategies. One of the key strategies that is emerging into the field is the ability to gene edit/modulate the immune cells, so that they are better prepared to deal with the cancers and avoid being inhibited by the tumour microenvironment.

This follows on from the panel discussion “The Therapeutic Gene Editing Solution – Cell Therapy for Solid Tumors” hosted by Horizon in October, with a core focus on base editing.

In this webinar, Dr John Lambourne - R&D Manager in Base Editing, Horizon Discovery and Danilo Maddalo, PhD - Group Leader, Translational Oncology, Genentech will discuss how CRISPR base editing is an innovative and safe gene editing solution for advanced cell and gene therapy.

Dr  Lambourne will also present Horizon’s Pin-Point™ base editing platform as a viable solution for therapeutic development.

  • How gene editing technologies have successfully been used to improve the next generation of C&GT 
  • That standard gene editing platforms can trigger off target effects that could hinder wider clinical application
  • Why emerging technologies, such as base editing, offer more precise, efficacious and safer gene editing for innovative development of more potent and cost-effective C&GT

Danilo Maddalo, PhD

Group Leader, Translational Oncology, Genentech

Danilo Maddalo got his PhD from the Karlsruhe Institute of Technology (Germany) and trained at Memorial Sloan Kettering Cancer Center (NYC, USA) before opening his first lab at the Novartis Institute for Biomedical Research (Basel, Switzerland). He is currently a group leader at Genentech (South San Francisco, USA) where he focuses on in vivo pharmacology, translational research and genome editing.

Dr. John Lambourne

Research and Development Manager, Horizon Discovery

Dr John Lambourne is a R&D Manager in Base Editing, Cell and Gene Therapy team of PerkinElmer’s Horizon Discovery business. Since joining the company in November 2018, his work has contributed towards the development and commercialisation of novel technologies for cell and gene therapy applications. He now works on driving the Pin-point™ base editing technology to its full potential in next generation therapeutics. 

SPEAKERS

Danilo Maddalo
Group Leader, Translational Oncology, Genentech

You might also like

Gain deeper insights into the mechanisms of immune cell killing of tumor cells:...

C Souders,
T Dale,
N Bevan et al.
Dr Colby Souders
Dr Colby Souders
Chief Scientific Officer, Abveris
Tim Dale, PhD
Tim Dale, PhD
Head of BioAnalytics Applications, Sartorius
Nicola Bevan
Nicola Bevan
Manager of Cell Imaging Applications, Sartorius
 Jeffrey Skolnik, M.D.
Jeffrey Skolnik, M.D.
Senior Vice President, Clinical Development, Inovio
6 October 2021
Watch now

The therapeutic gene editing solution – cell therapy for solid tumors

B Sasu,
P Sivakumar,
J Trager et al.
Barbra Sasu, PhD
Barbra Sasu, PhD
Chief Scientific Officer, Allogene Therapeutics
Pallavur Sivakumar, PhD
Pallavur Sivakumar, PhD
Scientific Vice President and Head of Discovery, Immuno-Oncology and Cell Therapy Thematic Research Center, Bristol Myers Squibb
James Trager, PhD
James Trager, PhD
Chief Scientific Officer, Nkarta Therapeutics
Jennifer Harbottle, PhD
Jennifer Harbottle, PhD
Senior Scientist, R&D, Cell and Gene Therapy, Horizon Discovery
30 September 2021
Watch now

Cell-based therapies for cancer treatment: leveraging advanced flow cytometry...

N Senutovitch,
R Fan,
T J.
Nina Senutovitch Ph.D.
Nina Senutovitch Ph.D.
Senior Scientist, Product Development, Cell Imaging, Sartorius
Professor Rong Fan
Professor Rong Fan
Professor of Biomedical Engineering, Yale University
Tamara J. Laskowski, Ph.D.
Tamara J. Laskowski, Ph.D.
Scientific Project Director, Adoptive Cell Therapy Platform, Dept. of Stem Cell Transplantation and Cellular Therapy MD Anderson Cancer Center
5 August 2021
Watch now

Key lessons for cell & gene therapy and mRNA therapeutic development from COVID-19...

S Zobbi,
V Indurthi,
C Kröner et al.
Scott Zobbi
Scott Zobbi
Senior Business Development Manager, Custom POROS Chromatography Resins, ThermoFisher Scientific
Venkata Indurthi, PhD
Venkata Indurthi, PhD
Vice President, Research and Development, Aldevron
Christoph Kröner
Christoph Kröner
Director DNA Process Development & Cap Technology, BioNTech SE
Joseph Barberio
Joseph Barberio
Director, Process Development at Strand Therapeutics Inc.
22 April 2021
Watch now

Evolving the role of gene editing in cell therapy

J Frampton,
T Thwaites,
T Meissner
Jonathan Frampton
Jonathan Frampton
Horizon Discovery at Horizon Discovery
Tristan Thwaites
Tristan Thwaites
Lead Technical Scientist at Cell and Gene Therapy Catapult
Torsten Meissner
Torsten Meissner
Postdoctoral Fellow, Department of Stem Cell & Regenerative Biology at Harvard Medical School
6 October 2020
Watch now